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As efforts accelerate to translate exosome biology into new medicines, clear technology gaps have emerged 
between the current state of the art for producing extracellular vesicles (EVs), comprising exosomes, and the 
capabilities necessary to support large scale clinical and commercial manufacturing. An allogenic EV production 
system is necessary to make the technology viable for a broad range of therapies and large patient populations. 
To this end, Codiak BioSciences has leveraged cutting edge bioprocessing methods developed through 
decades of recombinant protein manufacturing to create a >1,000-fold scalable exosome production platform 
based on an immortalized human cell line growing in suspension and chemically defined media. 
Until recently, EVs have been produced largely in discovery labs where process scale up and manufacturability 
were not of prime concern for this novel biotherapeutic modality. Using an established human cell line, we first 
developed a lab scale production process, which we then scaled up to bench scale and pilot scale through 
optimization of key process parameters, such as pH, gassing, and agitation. To expediently produce clinical 
material for our first program, we implemented a fed-batch process. However, with the goal for this platform to 
support a portfolio of clinical programs in the future, parallel efforts were focused on the development of a 
second generation production process using continuous technology. Importantly, our studies revealed a direct, 
positive correlation between bioreactor cell mass and EV productivity. Moreover, improvement in culture health 
was as important as the increase in biomass, since higher culture viabilities minimized contamination of the 
harvest with microvesicular and other membranous impurities, proteinaceous material, nucleic acids, and other 
small molecules—a positive outcome for downstream processing. Our results indicate that EVs can be 
efficiently produced in stirred-tank bioreactors in a fed-batch and continuous process representative of large 
scale manufacturing under GMP conditions. Due to process comparability at different platforms, the 
intermediate scales can be used to provide uniform batches of development material for discovery research. 
The EVs produced are strongly positive for canonical exosome markers such as tetraspanins, have classical 
exosome morphology by TEM, and are capable of fusing with recipient cells, although the effect of process 
manipulations on EV quality has not yet been fully understood. Lastly, our current process is robust, relies on 
standard bioprocessing infrastructure found at most CMOs and is compatible with single use disposable 
technology. 
 
